Venture financing ticks up for biopharma
But, with an ever-growing proportion of the cash going to a select few, the gulf between the haves and the have-nots is widening.
Big pharma holds steady on research spending
R&D spending by the world’s largest drug makers flatlined in 2022, with Roche footing the biggest bill and Astrazeneca the fastest accelerator.